Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a)

Taewoo Cho, Rocco Romagnuolo, Corey Scipione, Michael B. Boffa, and Marlys L. Koschinsky

Department of Biochemistry, Queen’s University, Kingston, ON K7L 3N6, Canada; Department of Chemistry and Biochemistry, University of Windsor, Windsor, ON N9B 3P4, Canada

ABSTRACT Lipoprotein(a) (Lp(a)) is associated with cardiovascular disease risk. This may be attributable to the ability of Lp(a) to elicit endothelial dysfunction. We previously reported that apolipoprotein(a) (apo(a); the distinguishing kringle-containing component of Lp(a)) elicits cytoskeletal rearrangements in vascular endothelial cells, resulting in increased cellular permeability. These effects require a strong lysine-binding site (LBS) in apo(a). We now report that apo(a) induces both nuclear β-catenin–mediated cyclooxygenase-2 (COX-2) expression and prostaglandin E2 secretion, indicating a proinflammatory role for Lp(a). Apo(a) caused the disruption of VE-cadherin/β-catenin complexes in a Src-dependent manner, decreased β-catenin phosphorylation, and increased phosphorylation of Akt and glycogen synthase kinase-3β, ultimately resulting in increased nuclear translocation of β-catenin; all of these effects are downstream of apo(a) attenuation of phosphatase and tensin homologue deleted on chromosome 10 activity. The β-catenin–mediated effects of apo(a) on COX-2 expression were absent using a mutant apo(a) lacking the strong LBS. Of interest, the normal and LBS mutant forms of apo(a) bound to human umbilical vein endothelial cells in a similar manner, and the binding of neither was affected by lysine analogues. Taken together, our findings suggest a novel mechanism by which apo(a) can induce proinflammatory and proatherosclerotic effects through modulation of vascular endothelial cell function.

INTRODUCTION

Results from epidemiological studies underscore an association between circulating lipoprotein(a) (Lp(a)) levels and risk for cardiovascular disease (Dubé et al., 2012; Tsimikas and Hall, 2012). Lp(a) contains a low-density-lipoprotein (LDL) moiety, as well as the unique glycoprotein apolipoprotein(a) (apo(a)), which is covalently linked to apolipoproteinB-100 (apoB-100) in LDL by a single disulfide bond resulting from the X-ray crystallography structure of human apo(a). (Koschinsky et al., 1993). Apo(a) shares a high degree of homology with the fibrinolytic proenzyme plasminogen and contains contiguous repeats of a sequence that closely resembles the plasminogen kringle IV domain, followed by domains homologous to the kringle V and protease domains of plasminogen (McLean et al., 1987). The kringle IV domains of apo(a) are divided into 10 types (McLean et al., 1987). Apo(a) contains a strong lysine-binding site (LBS) within the kringle IV type 10 (KIV10) sequence, which mediates the binding of apo(a) and Lp(a) to physiological ligands such as fibrin and extracellular matrix proteins (Hughes et al., 1997; Sangrar and Koschinsky, 2000). Moreover, the strong LBS within KIV10 of apo(a) was found to be absolutely required for apo(a)-mediated vascular endothelial dysfunction characterized by increased endothelial cell contraction and permeability via a Rho/Rho kinase–dependent pathway (Cho et al., 2008). Vascular endothelial cells represent the primary target of many physiological and pathological agents, such as thrombin, inflammatory cytokines, oxidized LDL (oxLDL), and Lp(a) (Wojciak-Stothard et al., 1998; Essler et al., 1999; Pellegrino et al., 2004). Many studies...
have shown that Lp(a), through its apo(a) component, exerts different effects on cells involved in the development of atherosclerotic lesions. For example, Lp(a)/apo(a) stimulates vascular smooth muscle cell proliferation and migration by inhibition of transforming growth factor-β (TGF-β) activation (O’Neil et al., 2004). In addition, Lp(a)/apo(a) enhances actin stress fiber formation and loss of cell–cell contact mediated in vascular endothelial cells; this is mediated by the apo(a) component of Lp(a) and leads to increased contraction of vascular endothelial cell monolayers (Pellegrino et al., 2004). Apo(a), through its strong LBS, induces disruption of adherens junctions measured by VE-cadherin dispersion, resulting in increased endothelial cell (EC) permeability (Cho et al., 2008). The composition of adherens junctions, where VE-cadherins associate with α-, β-, and γ-catenins, is a key determinant of the ability of the cell to regulate endothelial permeability and junction stability (Dejana et al., 2008). The effect of apo(a) on the composition of adherens junctions has not yet been investigated and as such formed a primary focus of the present study.

β-Catenin plays an important role in EC function. As a major component of the cell–cell adherens junctions, β-catenin links members of the cadherin family of transmembrane cell–cell adhesion receptors to the actin cytoskeleton (Ozawa et al., 1989). In quiescent cells, β-catenin is associated with VE-cadherin in complexes mainly at the plasma membrane, maintaining β-catenin in the cytoplasm at low levels. When liberated into the cytoplasm, β-catenin either translocates to the nucleus or becomes incorporated into a cytoplasmic complex with adenomatosis polyposis coli (APC), axin/conductin proteins, and glycogen synthase kinase-3β (GSK-3β), the last of which phosphorylates β-catenin on Ser-33, -37/Thr-41 sites; this leads to subsequent ubiquitination and proteasomal degradation of β-catenin (Behrens et al., 1998). If GSK-3β is inactivated by phosphorylation at Ser-9, the degradation of β-catenin is attenuated, and nuclear translocation of β-catenin is favored (Behrens et al., 1998). Within the nucleus, β-catenin functions as an activator of T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factors to stimulate transcription of variety of growth-related genes, including those encoding c-myc (Shutman et al., 1999), cyclin D1 (He et al., 1998), and cyclooxygenase-2 (COX-2; Kim et al., 2002; Araki et al., 2003; Barbieri and Weksler, 2007). COX enzymes catalyze the synthesis of prostaglandins (PGs) from arachidonic acid. COX-1 is expressed constitutively in most tissues and appears to be responsible for the production of PGs that control normal physiological functions, including platelet aggregation (Stemme et al., 2000). In contrast, COX-2 is not detected in most normal tissues but is rapidly induced by both inflammatory and mitogenic stimuli, resulting in increased PG synthesis associated with pathological processes, including acute and chronic inflammatory states (Stemme et al., 2000). Prostaglandin E2 (PGE2) is a major metabolite produced by COX-2 in EC, which influences vascular tone, regional blood flow, vascular permeability, and remodeling, proliferation, and angiogenesis (Dannenberg et al., 2005; Barbieri and Weksler, 2007).

Several lines of evidence suggest that phosphatase and tensin homologue deleted on chromosome 10 (PTEN) interacts indirectly with β-catenin by binding scaffolding proteins containing a PDZ domain, thus participating in regulating cell–cell junctions and vascular permeability (Kotelevets et al., 2005; Sanchez et al., 2007). PTEN is a lipid phosphatase that specifically dephosphorylates the D3 position of the inositol ring of the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3; Maehama and Dixon, 1998). PIP3 plays a critical role in the regulation of cell survival and growth signaling through activation of phosphatidylinositol-dependent kinases (PDKs) and their downstream target, protein kinase B (PKB)/Akt (Coffer et al., 1998). A number of studies demonstrated that overexpression of PTEN results in abrogation of Akt activity (Maehama et al., 2001). Consistent with this, both the cellular levels of PIP3 and those of Akt phosphorylation/activity are constitutively elevated in PTEN-deficient mouse embryonic fibroblasts (Sun et al., 1999). Thus PTEN is an upstream negative regulator of Akt through inactivation of PIP3. The carboxyterminal region of PTEN was shown to modulate its protein stability (Vazquez et al., 2006). Moreover, phosphorylation of the carboxyterminal residues Ser-380, Thr-382, and Thr-383 results in a sixfold increase in PTEN half-life, which suggests that phosphorylation plays an important role in regulating PTEN function (Vazquez et al., 2006).

On the basis of our previous findings (Pellegrino et al., 2004; Cho et al., 2008) indicating the ability of apo(a) to disrupt adherens junctions, in the present study we address potential consequences of β-catenin release from these junctions relevant to the proatherosclerotic and proinflammatory roles ascribed to Lp(a) in the vasculature.

RESULTS

Apo(a), through its strong LBS, stimulates VE-cadherin/β-catenin complex dissociation

We previously demonstrated that apo(a), via its strong LBS in KIV10, mediates VE-cadherin dispersion and actinomyosin-derived EC contraction, resulting in increased endothelial permeability (Pellegrino et al., 2004; Cho et al., 2008). To illustrate a direct effect of apo(a) on disruption of adherens junctions, we investigated the dissociation of β-catenin from the complex by immunostaining and immunoprecipitation in response to treatment of EC with two different forms of apo(a) (Figure 1): 17K contains all of the domains found in all apo(a) isoforms and, in fact, represents a physiologically relevant isoform (Koschinsky et al., 1991); 17KΔAsp is identical to 17K except for a single–amino acid substitution that abolishes the strong LBS in KIV10 (Cho et al., 2008).

After a brief, 15-min, serum starvation, confluent human umbilical vein endothelial cells (HUVECs) displayed organized β-catenin and VE-cadherin as slender lines along the margin of the cells (Figure 2A), representing their localization in adherens junctions. Treatment with 200 nM 17K caused time-dependent dispersion of β-catenin and VE-cadherin and the formation of intercellular gaps (Figure 2A). Consistent with an important role of the strong LBS in KIV10 of apo(a) in mediating EC responses (Cho et al., 2008),

![Recombinant apo(a) variants used in this study. Schematic diagram shows the topology of the r-apo(a) variants. 17K represents a physiologically relevant apo(a) isoform and contains all of the kringle domains present in all apo(a) isoforms. The numbering of KIV types is provided at the top. A dot in KIV represents a single–amino acid substitution, which abolishes strong lysine-binding sites. The bar over KIV signifies absence of the strong LBS. 17K represents a physiologically relevant apo(a) isoform and contains all of the kringle domains present in all apo(a) isoforms. The numbering of KIV types is provided at the top. A dot in KIV represents a single–amino acid substitution, which abolishes strong lysine-binding sites. The bar over KIV signifies absence of the strong LBS.](image-url)
FIGURE 2: A strong lysine-binding site in Kv10 is required for stimulation of VE-cadherin/β-catenin complex dissociation. (A) HUVECs were serum starved for 15 min and then treated with 200 nM of r-apo(a) variants (17K or 17KΔAsp) for the indicated times. Cells were then fixed, permeabilized, and stained for VE-cadherin and β-catenin, as indicated, as described in Materials and Methods. (B) HUVECs were pretreated with 10 μM PP1 for 1 h; control cells were not pretreated with PP1. Then, all cells were either treated or not treated with 200 nM 17K for 10 min. Cell lysates were prepared and subjected to Western blot analysis using either β-catenin or VE-cadherin antibodies in order to assess the extent of association of these two proteins. The intensity of the respective bands was measured densitometrically; the graph shows mean band density (normalized to the control) ± SE of three independent experiments, with the asterisks representing significant differences (p < 0.05) compared with the control.
17KΔAsp did not alter β-catenin or VE-cadherin dissociation or the gap formation in the EC monolayer. To definitively assess dissociation of β-catenin from adherens junctions, we performed a quantitative analysis using immunoprecipitation. We immunoprecipitated VE-cadherin in lysates of treated cells and then subjected the immunoprecipitated material to Western blot analysis using anti–β-catenin antibodies. These analyses demonstrated that 17K, in a concentration-dependent manner, induced a marked decrease of β-catenin in the VE-cadherin complex (Figure 2B); 17K concentrations of 200 nM or greater resulted in a significant increase in β-catenin complex dissociation. Therefore 200 nM apo(a) was used for subsequent experiments.

The tyrosine phosphorylation of VE-cadherin and other components of adherens junctions is associated with weak junctions and impaired barrier function. Many studies have reported that permeability-increasing agents such as histamine (Shasby et al., 2002), tumor necrosis factor-α (Angelini et al., 2006), and vascular endothelial cell growth factor (Esser et al., 1999) induce the tyrosine phosphorylation of VE-cadherin and its binding partners, β-catenin, plakoglobin, and p120. Although the mechanism of VE-cadherin complex phosphorylation has not been fully clarified, Src plays a major role in phosphorylating tyrosine residues of proteins in the complex (Dejana et al., 2008). To investigate whether Src is involved in dissociation of β-catenin induced by 17K, we incubated HUVECs with a potent pharmacological inhibitor of Src (PP1) before treatment with apo(a). Indeed, PP1 effectively blocked 17K-mediated dissociation of β-catenin from the VE-cadherin complex (Figure 2B).

Apo(a), through its strong LBS, mediates β-catenin nuclear accumulation

After dissociation from membrane-associated adherens junctions into the cytoplasm, β-catenin either translocates to the nucleus or becomes incorporated into an APC complex that favors protein degradation (Ozawa et al., 1989; Behrens et al., 1998). Exposing HUVECs to 17K stimulated translocation of β-catenin to the nucleus (Figure 3A). Concomitantly, the level of β-catenin in the cytoplasmic extract decreased as the time of 17K treatment increased. On the other hand, 17KΔAsp showed no effect on β-catenin nuclear translocation. Interleukin-1β (2 ng/ml) and plasminogen (400 nM) were used as positive and negative controls, respectively, and showed the expected increase and lack of effect on β-catenin translocation.

Incubation of HUVECs with a phosphoinositide 3-kinase (PI3K) inhibitor (LY294002) or ε-aminocaproic acid (ε-ACA), a lysine analogue, before 17K treatment completely abolished the 17K-mediated effects. Treatment with the Src inhibitor PP1 resulted in a reduction in 17K-mediated nuclear translocation of β-catenin, indicating that tyrosine phosphorylation by Src is at least partially involved in the process of β-catenin trafficking (Figure 3B). Of interest, the Rho kinase inhibitor Y27632 did not prevent 17K-mediated β-catenin translocation in the present study (unpublished data), although it was a potent inhibitor for 17K-mediated Rho/Rho kinase–dependent increase in EC contraction and permeability in our previous study (Pellegrino et al., 2004; Cho et al., 2008). These findings, collectively, indicate that 17K uses a Rho/Rho kinase–independent signaling pathway involving PI3K to mediate β-catenin nuclear translocation.

17K, but not 17KΔAsp, induces COX-2 expression in HUVECs in a manner dependent on PI3K

β-Catenins present in the nucleus act as a transcription cofactor with the TCF/LEF family of DNA-binding proteins to modify expression of many inflammatory genes, including COX-2 (Kim et al., 2002; Araki et al., 2003; Barbieri and Weksler, 2007). To determine whether apo(a) influences COX-2 expression, we exposed HUVECs to 17K and analyzed COX-2 expression by Western blot analysis. As shown in Figure 4A, 200 nM 17K induced COX-2 protein expression in a time-dependent manner. 17K increases COX-2 expression to a maximal extent at 7 h of stimulation, whereas 17K concentrations <100 nM did not influence COX-2 expression (unpublished data). After 7 h of 17K treatment, COX-2 expression declined yet remained at a level far above

**FIGURE 3:** A strong lysine-binding site in KIV₁₀ enhances nuclear β-catenin translocation in HUVECs. (A) HUVECs were serum starved for 15 min and then treated with 200 nM 17K or 17KΔAsp for the indicated times. Total nuclear proteins were harvested and subjected to Western blot analysis using anti–β-catenin or anti–RNA polymerase II antibodies. IL-1β and plasminogen were used as positive and negative controls, respectively. (B) Cells were pretreated with LY294002 (5 μM, 1 h) and PP1 (10 μM, 1 h) and then were incubated with 17K (200 nM) for the indicated time periods (0–40 min). In some experiments, ε-ACA (80 mM) was included with the 17K. Graphs show mean band density (normalized to the control) ± SE of three independent experiments; representative Western blots are shown below the graphs. Symbols above the plots represent significant differences (p < 0.05) compared with the control for different treatments represented by the corresponding plot symbols in each panel (as shown in the graph legends).
FIGURE 4: 17K induces COX-2 activation and PGE₂ secretion. (A, B) HUVECs were treated with serum-depleted medium containing 17 K (200 nM) or IL-1β (2 ng/ml) for the up to 24 h. At specific time points, cell lysates were prepared and subjected to Western blot analysis using COX-2 antibody while the corresponding media were collected to measure PGE₂ levels. (C) HUVECs were treated for 7 h with 200 nM 17K or 17KΔAsp or with 200 nM 17K and 5 μM LY294002 (after a 1-h pretreatment with LY294002). Cell lysates were prepared and subjected to Western blot analysis using COX-2 antibody (D), and the corresponding media were collected to measure PGE₂ levels (E). Graphs show mean band density (normalized to the control) ± SE of three independent experiments, and representative Western blots of three independent experiments are shown. The asterisks represent significant differences (p < 0.05) compared with controls.
expression (unpublished data). Treatment with LY294002 completely inhibited 17K-mediated effects on COX-2 expression in HUVECs (Figure 4C), whereas expression of the constitutively expressed enzyme COX-1 was not modified after treatment with 17K (unpublished data).

An increase in COX-2 protein levels in endothelial cells leads to up-regulation of PGE\(_2\) production and secretion to induce inflammatory and atherogenic effects (Sanchez et al., 2007). Both 17K and IL-1\(\beta\) up-regulated PGE\(_2\) release to the media in HUVECs (Figure 4D). 17K\(\Delta\)Asp did not affect PGE\(_2\) release, in agreement with its lack of effect on COX-2 expression (Figure 4E). Furthermore, LY294002 completely abolished PGE\(_2\) release mediated by 17K (Figure 4E).

Apo(a)-mediated accumulation of \(\beta\)-catenin in the nucleus is required for the effect of apo(a) on COX-2 expression and PGE\(_2\) production

To determine whether \(\beta\)-catenin was directly involved in regulating COX-2 expression by apo(a), we first transfected HUVECs with \(\beta\)-catenin small interfering RNA (siRNA) or with a nonspecific siRNA and then exposed them to different concentrations of apo(a) (200 or 600 nM). Transfection of HUVECs with siRNA directed against \(\beta\)-catenin markedly decreased levels of nuclear \(\beta\)-catenin compared with cells transfected with nonspecific siRNA (Figure 5A). Treatment of the cells transfected with nonspecific siRNA with 17K resulted in an increase in nuclear \(\beta\)-catenin, whereas treatment of the cells transfected with \(\beta\)-catenin siRNA did not result in the appearance of nuclear \(\beta\)-catenin. Accordingly, transfection of the cells with \(\beta\)-catenin siRNA abolished the 17K-mediated increase in COX-2 expression, whereas the nonspecific siRNA did not (Figure 5A). Moreover, the \(\beta\)-catenin siRNA completely abolished the 17K-dependent increase in PGE\(_2\) secretion (Figure 5B). These results are an indication that increased COX-2 expression leading to enhanced PGE\(_2\) secretion as a consequence of 17K treatment is directly mediated by 17K-induced nuclear translocation of \(\beta\)-catenin. Consistent with previous findings, the 17K-mediated increase in COX-2 expression was also completely abolished by treatment of cells with \(\varepsilon\)-ACA (Figure 5C).

**FIGURE 5:** The role of \(\beta\)-catenin in regulation of COX-2 expression by apo(a). (A) HUVECs were transfected with \(\beta\)-catenin siRNA or nonspecific siRNA as described in Materials and Methods and then stimulated for 7 h with 17K. Representative Western blots for \(\beta\)-catenin nuclear translocation and COX-2 expression in three independent experiments are analyzed. (B) COX activity as measured by secretion of PGE\(_2\) into culture media of cells treated for 0 or 7 h with apo(a) that had been transfected with \(\beta\)-catenin siRNA or nonspecific siRNA. Shown are the means \(\pm\) SE of three independent experiments, each performed in duplicate. The asterisks represent significant differences \((p < 0.05)\) compared with the control. (C) Representative Western blot (of three independent experiments) showing the effect of 17K treatment on COX-2 expression in the presence or absence of \(\varepsilon\)-ACA (80 mM).

that observed in the control (Figure 4A). Interleukin-1\(\beta\) (IL-1\(\beta\); 2 ng/ml) was used as positive control (Figure 4B) and resulted in a maximal extent of COX-2 inhibition that was approximately sixfold higher than that observed with 17K. Consistent with its lack of effect on \(\beta\)-catenin nuclear translocation, 17K\(\Delta\)Asp failed to increase COX-2 expression (unpublished data). Treatment with LY294002 completely inhibited 17K-mediated effects on COX-2 expression in HUVECs (Figure 4C), whereas expression of the constitutively expressed enzyme COX-1 was not modified after treatment with 17K (unpublished data).

An increase in COX-2 protein levels in endothelial cells leads to up-regulation of PGE\(_2\) production and secretion to induce inflammatory and atherogenic effects (Sanchez et al., 2007). Both 17K and IL-1\(\beta\) up-regulated PGE\(_2\) release to the media in HUVECs (Figure 4D). 17K\(\Delta\)Asp did not affect PGE\(_2\) release, in agreement with its lack of effect on COX-2 expression (Figure 4E). Furthermore, LY294002 completely abolished PGE\(_2\) release mediated by 17K (Figure 4E).

Apo(a)-mediated accumulation of \(\beta\)-catenin in the nucleus is required for the effect of apo(a) on COX-2 expression and PGE\(_2\) production

To determine whether \(\beta\)-catenin was directly involved in regulating COX-2 expression by apo(a), we first transfected HUVECs with \(\beta\)-catenin small interfering RNA (siRNA) or with a nonspecific siRNA and then exposed them to different concentrations of apo(a) (200 or 600 nM). Transfection of HUVECs with siRNA directed against \(\beta\)-catenin markedly decreased levels of nuclear \(\beta\)-catenin compared with cells transfected with nonspecific siRNA (Figure 5A). Treatment of the cells transfected with nonspecific siRNA with 17K resulted in an increase in nuclear \(\beta\)-catenin, whereas treatment of the cells transfected with \(\beta\)-catenin siRNA did not result in the appearance of nuclear \(\beta\)-catenin. Accordingly, transfection of the cells with \(\beta\)-catenin siRNA abolished the 17K-mediated increase in COX-2 expression, whereas the nonspecific siRNA did not (Figure 5A). Moreover, the \(\beta\)-catenin siRNA completely abolished the 17K-dependent increase in PGE\(_2\) secretion (Figure 5B). These results are an indication that increased COX-2 expression leading to enhanced PGE\(_2\) secretion as a consequence of 17K treatment is directly mediated by 17K-induced nuclear translocation of \(\beta\)-catenin. Consistent with previous findings, the 17K-mediated increase in COX-2 expression was also completely abolished by treatment of cells with \(\varepsilon\)-ACA (Figure 5C).

**FIGURE 5:** The role of \(\beta\)-catenin in regulation of COX-2 expression by apo(a). (A) HUVECs were transfected with \(\beta\)-catenin siRNA or nonspecific siRNA as described in Materials and Methods and then stimulated for 7 h with 17K. Representative Western blots for \(\beta\)-catenin nuclear translocation and COX-2 expression in three independent experiments are analyzed. (B) COX activity as measured by secretion of PGE\(_2\) into culture media of cells treated for 0 or 7 h with apo(a) that had been transfected with \(\beta\)-catenin siRNA or nonspecific siRNA. Shown are the means \(\pm\) SE of three independent experiments, each performed in duplicate. The asterisks represent significant differences \((p < 0.05)\) compared with the control. (C) Representative Western blot (of three independent experiments) showing the effect of 17K treatment on COX-2 expression in the presence or absence of \(\varepsilon\)-ACA (80 mM).

Apo(a)-mediated accumulation of \(\beta\)-catenin in the nucleus is required for the effect of apo(a) on COX-2 expression and PGE\(_2\) production

To determine whether \(\beta\)-catenin was directly involved in regulating COX-2 expression by apo(a), we first transfected HUVECs with \(\beta\)-catenin small interfering RNA (siRNA) or with a nonspecific siRNA and then exposed them to different concentrations of apo(a) (200 or 600 nM). Transfection of HUVECs with siRNA directed against \(\beta\)-catenin markedly decreased levels of nuclear \(\beta\)-catenin compared with cells transfected with nonspecific siRNA (Figure 5A). Treatment of the cells transfected with nonspecific siRNA with 17K resulted in an increase in nuclear \(\beta\)-catenin, whereas treatment of the cells transfected with \(\beta\)-catenin siRNA did not result in the appearance of nuclear \(\beta\)-catenin. Accordingly, transfection of the cells with \(\beta\)-catenin siRNA abolished the 17K-mediated increase in COX-2 expression, whereas the nonspecific siRNA did not (Figure 5A). Moreover, the \(\beta\)-catenin siRNA completely abolished the 17K-dependent increase in PGE\(_2\) secretion (Figure 5B). These results are an indication that increased COX-2 expression leading to enhanced PGE\(_2\) secretion as a consequence of 17K treatment is directly mediated by 17K-induced nuclear translocation of \(\beta\)-catenin. Consistent with previous findings, the 17K-mediated increase in COX-2 expression was also completely abolished by treatment of cells with \(\varepsilon\)-ACA (Figure 5C).

**Apo(a) reduces \(\beta\)-catenin degradation to facilitate \(\beta\)-catenin nuclear translocation**

\(\beta\)-Catenin accumulation in the nucleus requires not only its release from membrane complexes with VE-cadherin (Figure 2B), but also decreased degradation in the cytoplasm by the ubiquitin/proteasome


The rapid increase of Akt and GSK-3β phosphorylation was entirely suppressed by LY294002 treatment, consistent with its effects on 17K-mediated changes in β-catenin phosphorylation, β-catenin nuclear translocation, COX-2 expression, and PGE₂ secretion (Figures 3, 4, and 6).

The activation of PTEN may prevent phosphorylation of tyrosine residues on β-catenin and PI3K signaling events that are required to modulate permeability of endothelial monolayers (Vazquez and Sellers, 2000; Link to Vazquez and Sellers, 2000; Vogelmann et al., 2005). PTEN is negatively regulated by phosphorylation of residues Ser-380 and Thr-382/383 (Vazquez et al., 2006). Therefore, we assessed the effect of apo(a) treatment of cultured HUVECs on PTEN phosphorylation. Ten minutes of 17K treatment resulted in increased phosphorylation of Ser-380 and Thr-382/383 in HUVECs (Figure 8). Consistent with a recent study (Barbieri et al., 2008) and our findings, interleukin-1β (2 ng/ml) increased phosphorylation of PTEN at the Ser-380, Thr-382/383 sites, whereas 17KΔAsp had no effect on PTEN phosphorylation (Figure 8). Taken together, these data support the hypothesis that apo(a)-induces activation of a PI3K/Akt/GSK-3β-dependent pathway PI3K through inhibition of its negative regulator PTEN and enhances β-catenin nuclear translocation, with subsequent effects on COX-2 expression and PGE₂ secretion from the cells.

To assess whether the effects of apo(a) on HUVECs could be correlated with binding of apo(a) to these cells, we performed a binding experiment using fluorescently labeled 17K, 17KΔAsp, and plasminogen (Figure 9). Of interest, there was no difference in binding observed between the two apo(a) variants. In addition, the binding of neither apo(a) variant was diminished by the addition of ε-ACA, although, as expected, the binding of plasminogen was markedly diminished by this lysine analogue.

DISCUSSION

There is strong evidence to suggest that elevated concentrations of plasma Lp(a) (>25 mg/dl) are a risk factor for a variety of cardiovascular diseases, including coronary heart disease, ischemic stroke, and venous thrombosis (Dubé et al., 2012; Tsimikas and Hall, 2012). The ability of Lp(a) to induce vascular inflammation and endothelial dysfunction appears to be a common link among these diseases. Studies suggest roles for apo(a) as a proatherosclerotic factor, with
is clear that the apo(a) portion of Lp(a) is the active moiety. Therefore the activation of apo(a)-induced inflammatory responses in the vasculature is expected to be important for the cascade of events that culminates in the formation of atherosclerotic lesions.

We hypothesized, on the basis of our previous findings that apo(a) induces disruption of adherens junctions (Pellegrino et al., 2004; Cho et al., 2008), that this could, in turn, release β-catenin for subsequent nuclear translocation and induction of gene expression, including the proinflammatory COX-2. Accordingly, we now demonstrate that 17K apo(a) treatment of EC enhances the disruption of the VE-cadherin/β-catenin complex and nuclear translocation of β-catenin, resulting in up-regulation of COX-2 expression and PGE\(_2\) secretion in ECs. Our findings thus suggest another novel mechanism by which apo(a) contributes to atherogenesis other than through activation of Rho/Rho kinase–dependent pathway as we previously described (Pellegrino et al., 2004). PGE\(_2\) is a potent regulator of vascular inflammation and affects numerous mechanisms that have been implicated in carcinogenesis and atherogenesis, including stimulation of cell proliferation and motility, while inhibiting immune surveillance and apoptosis (Krysan et al., 2008).

Our experiments defined the intracellular pathway stimulated by apo(a) that culminates in changes in COX-2 expression (Figure 10). In addition to disruption of VE-cadherin/β-catenin complexes, treatment of vascular EC with apo(a) attenuates the phosphorylation of β-catenin at Ser-33,-37/Thr-41 by GSK-3β (Figure 6), thus causing a most of the pathological effects by which it contributes to vascular dysfunction mediated through the unique glycoprotein moiety, apo(a) (Koschinsky and Marcovina, 2009). In this regard, we previously demonstrated that the apo(a) component of Lp(a) induces cytoskeleton rearrangements that promote an increase in EC contraction and permeability (Pellegrino et al., 2004). Because LDL and plasminogen have no effect in this regard (Pellegrino et al., 2004), it

FIGURE 7: Apo(a) activates the PI3K/Akt pathway in manner dependent upon the strong lysine binding in KIV\(_{10}\). HUVECs were serum starved for 15 min and treated with 200 nM 17K or 17KΔAsp or with 17K plus ε-ACA (80 mM) for the indicated time periods. Total cellular proteins were harvested and subjected to Western blot analysis using specific anti–phospho-Akt (Ser-473) antibody (A) or anti–phospho-Akt (Thr-308) antibody (B). In some experiments, cells were pretreated with LY294002 (5 μM) for 1 h. The graphs show the band intensities (means ± SE; normalized to total Akt as determined by Western blot analysis) obtained from three independent experiments, where asterisks represent significant increases after 17K treatment (p < 0.05) compared with the control; squares show significant increases after IL-1β treatment (p < 0.05) compared with control. Representative Western blots are shown below the graphs.

FIGURE 8: Apo(a) inhibits PTEN activity through its phosphorylation of serine/threonine residues. HUVECs were serum starved for 15 min and treated with 200 nM 17K or 200 nM 17KΔAsp for the indicated time periods. Total cellular proteins were harvested and subjected to Western blot analysis using specific anti–phospho-PTEN (Ser-380, Thr-382/-383) antibody. II-1β (2 ng/ml) was used as a positive control. The graphs show the band intensities (means ± SE; normalized to total PTEN as determined by Western blot analysis) obtained from three independent experiments, where asterisks represent significant increases after 17K treatment (p < 0.05) compared with the control; squares show significant increases after IL-1β treatment (p < 0.05) compared with control. Representative Western blots are shown below the graphs.
decrease in the degradation of cytoplasmic β-catenin. Akt is a critical regulator of PI3K-mediated inactivation of GSK-3β (Cross et al., 1995). On agonist stimulation, the PH domain of Akt binds to the lipid products of PI3K, and Akt is recruited to the plasma membrane. It is then sequentially phosphorylated at Thr-308 and Ser-473 by upstream kinases referred to as 3-phosphoinositide-dependent protein kinase 1 (PDK1) and PDK2, respectively, to yield a fully activated kinase (Hemmings, 1997; Downward, 1998). We show that apo(a) increases phosphorylation of both sites for a full activation of Akt (Figure 7), which can then phosphorylate GSK-3β at Ser-9 (Figure 6). Ser-9 phosphorylation completely abolishes the activity of GSK-3β. This favors β-catenin nuclear translocation by reducing the degradation signal mediated by the phosphorylation of β-catenin at serine/threonine residues by GSK-3β. Accordingly, addition of a pharmacological inhibitor of PI3K, LY294002, decreased Akt activation and GSK-3β inactivation mediated by apo(a), enhanced phosphorylation and degradation of β-catenin, reduced nuclear β-catenin accumulation, and decreased COX-2 expression and PGE2 secretion. Our findings are consistent with a recent study in mouse cardiac endothelial cells demonstrating that tobacco smoke–induced nuclear translocation of β-catenin to induce COX-2 expression is mediated by a PI3K/Akt/GSK-3β pathway (Barbieri and Weksler, 2007).

We demonstrate here for the first time that apo(a) inactivates PTEN by causing phosphorylation of serine/threonine residues of the PTEN tail (Figure 8), suggesting a direct pathway for modulation of PTEN activity by apo(a). Casein kinase-2 (CK2) is one of the major kinases that reduce catalytic activity of PTEN with consequent activation of PI3K/Akt pathway. CK2-mediated phosphorylation also stabilizes PTEN in a monomeric “closed” conformation with low affinity for β-catenin/scaffolding protein complex (Vazquez et al., 2001). Our present findings suggest that induction of serine/threonine phosphorylation and inactivation of PTEN modulated by apo(a) may be regulated through CK2 since active Src increases phosphorylation and catalytic activity of this kinase (Donella-Deana et al., 2003; Hildesheim et al., 2005). Indeed, we show that Src is implicated in apo(a)-mediated disruption of adherens junctions and in reduction of β-catenin nuclear accumulation (Figure 2B). Further investigation of the effect of apo(a) in EC, focusing on the involvement of CK2, would give us a better understanding of how apo(a) activates the PI3K/Akt pathway through modulation of PTEN.

Our research thus far has demonstrated that the strong LBS in apo(a) kringles IV type 10 is absolutely required for apo(a)-mediated changes in cytoskeletal rearrangements and enhanced EC contraction and permeability (Pellegrino et al., 2004; Cho et al., 2008). Consistent with this finding, we show here that β-catenin–mediated effects of apo(a) on increased COX-2 expression, which results in PGE2 secretion, were not evident when apo(a) lacking the strong LBS in KIV type 10 (17KAsp) was used. Furthermore, 17KAsp failed to increase PTEN phosphorylation or phosphorylation of any PI3K downstream effectors that lead to inactivation of GSK-3β. In addition, treatment with ε-ACA, a lysine analogue, completely abolished all of the apo(a)-induced effects, consistent with a role for the strong LBS in apo(a). Plasminogen, which shares a striking homology with apo(a) and contains an LBS with similar lysine affinity to that of apo(a), did not affect any of the above-mentioned effects of apo(a). Therefore it is clear that the LBS in apo(a) is able to mediate effects of plasminogen with its multiple LBS cannot. However, whether apo(a) works through known plasma membrane receptors or binds to a novel receptor to exert its function is not known and is under investigation by our group.

As a first step toward identifying the receptors(s) to which apo(a) binds, we studied the binding of apo(a) to HUVECs. We made the surprising finding that removal of the strong LBS in KIV10 of apo(a)
was not required for binding and that the binding of both apo(a) variants was insensitive to the addition of the lysine analogue ε-ACA. These data clearly indicate that signaling by apo(a) can be dissociated from cell binding of apo(a) per se. Many different receptors have been proposed for apo(a), including Mac-1 on macrophages (Sotiriou et al., 2006) and plasminogen receptors on hepatocytes (Tam et al., 1996). Of note, none of these are signaling receptors in their own right. A possible way to reconcile these findings comes from the work of the Tabas group, who found that apo(a) acts through CD36/Toll-like receptor 2 (TLR2) to promote apoptosis in macrophages undergoing ER stress (Seimon et al., 2010). Of interest, TLR2 has been shown to operate through activation of both PI3K and Src (Arbibe et al., 2000; Janssens and Beyaert, 2002; Manukyan et al., 2009) and as such is a plausible candidate for the apo(a) signaling receptor on HUVECs. Of note, it is the oxidized phospholipids that are covalently attached to apo(a) that appear to be the active signaling molecules in the context of ER-stressed macrophages. It is tempting to speculate that the same holds true for proinflammatory apo(a) signaling in endothelial cells.

In conclusion, we have characterized a signal transduction pathway by which apo(a), through its strong LBS in KIV<sub>10</sub>, increases activation of PI3K/Akt/GSK-3β pathways and thus stimulates accumulation of NFXβ and β-catenin in the nucleus, the latter of which up-regulates COX-2 expression with a concomitant increase in secretion of PGE<sub>2</sub>. It will be interesting to assess whether apo(a) is able to modulate the expression of other genes involved in the atherosclerotic process through this pathway. In addition, apo(a) mediates Src-dependent disruption of VE-cadherin/β-catenin complexes, which would contribute to EC permeability. Taken together, our results suggest novel mechanisms by which apo(a) can contribute to the initiation and development of cardiovascular diseases.

**MATERIALS AND METHODS**

**Expression and purification of recombinant apo(a)**

A 17-kringle (17K)-containing form of recombinant apo(a) (17K r-apo(a)), as well as a mutant form of 17K r-apo(a) (17KA<sub>Asp</sub>) containing an Asp → Ala substitution at amino acid position 56 that abolishes the strong LBS in the KIV<sub>10</sub> domain (Figure 1), were constructed and expressed as previously described (Koschinsky et al., 1991; Sangrar et al., 1997). Both r-apo(a) species were purified from the conditioned medium (CM) of stably expressing human embryonic kidney 293 cell lines by lysine–Sepharose (Amersham Biosciences, Piscataway, NJ) affinity chromatography as previously reported (Sangrar et al., 1997).

**Cell culture**

Primary HUVECs were obtained from Clonetics (San Diego, CA) and grown in complete medium (endothelial basal medium EBM-2 and endothelial growth medium EGM-2 [Clonetics] containing 2% fetal calf serum) as specified by the manufacturer. Cells were used at passages 3–6.

**Double immunofluorescence**

For double-immunofluorescence studies, cells were plated onto gelatin precoated (1 h, 0.1% gelatin [Fisher Scientific, Pittsburgh, PA]) at 37°C glass coverslips at a density of 25,000 cells/well in 24-well tissue culture dishes and grown to near confluence. Before treatment with r-apo(a), cells were serum starved for 15 min at 37°C in EBM-2 (Clonetics). This solution was then replaced with fresh EBM-2 containing 200 nM apo(a) variants, and the cells were incubated at 37°C for 10 or 40 min. Cells were then prepared for double immunofluorescence as follows. Cells were fixed with 3.7% paraformaldehyde solution in phosphate-buffered solution (PBS) for 5 min, washed once with PBS, and permeabilized with 1.4% formaldehyde containing 0.1% Nonidet P-40 (NP-40) in PBS for 1.5 min, and then washed three times with PBS. Cells were incubated for 1 h at room temperature with both an anti-VE-cadherin monoclonal antibody (Research Diagnostics, Flanders NJ) and an anti-β-catenin antibody raised in rabbits (Sigma-Aldrich, St. Louis, MO), each diluted 1:350 in saponin buffer (0.1% saponin, 20 mM KPO<sub>4</sub>, 10 mM 1,4-piperazinediethanesulfonic acid, 5 mM ethylene glycol tetraacetetic acid, 2 mM MgCl<sub>2</sub>, pH 6.8). After three washes with PBS, cells were stained for 1 h with 1:500-diluted goat anti–mouse Alexa 488–conjugated antibody and goat anti–rabbit Alexa 568–conjugated antibody (Molecular Probes, Eugene, OR) in saponin buffer in the dark. After three washes with PBS, coverslips were mounted on slides using an antifade mounting solution (Dako, Carpinteria, CA) and examined using a Zeiss Axiosvert S100 inverted fluorescence microscope equipped with a 40x oil immersion lens (Carl Zeiss, Jena, Germany). Images were captured using a high-sensitivity Cooke SensiCam and SlideBook software (Intelligent Imaging Innovations, Denver, CO).

**Protein preparation and analysis**

For Western blotting of total cellular extracts, HUVECs were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 1% [vol/vol] NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mM Na<sub>2</sub>VO<sub>4</sub>, and 1 mM NaF) and added to 6x SDS sample buffer as previously described (Cho et al., 2008). Samples were subjected to SDS–PAGE using polyacrylamide gels of an appropriate percentage, and resolved proteins were transferred to Immobilon P membranes (Millipore, Billerica, CA) in transfer buffer (25 mM Tris, 192 mM glycine, 10% [vol/vol] methanol). The membranes were blocked in 4% (wt/vol) milk in TBST (10 mM Tris, pH 7.4, 150 mM NaCl, 0.5% [vol/vol] Tween 20) for 30 min and then incubated overnight at 4°C with primary antibody in blocking buffer against either anti–COX-2 (polyclonal antibody; Cayman Chemical Company, Ann Arbor, MI) or COX-1 (monoclonal antibody; Cayman Chemical Company); anti–phospho-Akt (Ser-473 and Thr-308), total Akt, anti–phospho-GSK-3β (Ser-9), anti–phospho-β-catenin (Ser-33, -37/Thr-41), anti–phospho-PTEN (Ser-380, Thr-382/-383), total PTEN, anti–phosphorylated (Ser-32) IκBα, and total IκBα from Cell Signaling Technology (Beverly, MA); and β-actin (Sigma-Aldrich). A detailed protocol for each antibody was followed as described in the corresponding manufacturer’s protocol. Blots were subsequently incubated with horseradish peroxidase (HRP)–conjugated donkey anti–mouse, goat anti–rabbit, and bovine anti–goat (Santa Cruz Biotechnology, Santa Cruz, CA) immunoglobulin G (IgG), as appropriate, and visualized using enhanced chemiluminescence (ECL) Western blot detection reagents (Amersham Biosciences) and exposed to x-ray film. Densitometric analysis of the bands was performed using Corel Photopaint, version 11 (Corel, Mountain View, CA).

For the preparation of nuclear extracts, cells were suspended in hypotonic buffer A (10 mM 4-(2-hydroxyethyl)-1-piperazinediethanesulfonic acid [HEPES], pH 7.6, 10 mM KCl, 0.1 mM MgCl<sub>2</sub>, 0.1 mM dithiothreitol, 0.1 mM EDTA, 0.5 mM PMSF, and 1 mM each of pepstatin, aprotinin, and leupeptin) for 10 min in ice and vortexed for 10 s. Nuclei were pelleted by centrifugation and washed with buffer B (10 mM HEPES, pH 7.6, 400 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.1 mM EDTA, 0.1 mM NaF, 0.5 mM PMSF, 1 μM each of pepstatin, aprotinin, and leupeptin, and 5% [vol/vol] glycerol) for 30 min on ice. The supernatants containing nuclear proteins
were collected by centrifugation at 12,000 × g for 20 min (Barbieri and Weksler, 2007). Samples were prepared using SDS-sample buffer and subjected to SDS–PAGE using the appropriate percentage polyacrylamide gel. Membranes were probed using anti–β-catenin (BD Transduction Laboratories, Lexington, KY), anti-NFκB (Cell Signaling Technology), or anti–RNA polymerase II (Millipore) monoclonal antibodies in 4% (vol/vol) milk in TBST. Washed membranes were incubated with HRP-conjugated anti–mouse IgG secondary antibody (Santa Cruz Biotechnology) and developed using ECL reagents.

Inhibitors, including a Rho kinase inhibitor (Y27632), a PI3 kinase inhibitor (LY294002), and an Src inhibitor (PP1 Analog II), were purchased from Calbiochem (La Jolla, CA) and used to pretreat the cells as described in the figure legends.

**Immunoprecipitation**

HUVECs were grown in six-well tissue culture plates and lysed in immunoprecipitation buffer (62.5 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% [vol/vol] Nonidet P-40, 0.1% Tween 20, 1 mM Na₂VO₃, 1 mM PMSF, protease inhibitor cocktail) for 30 min on ice. A monoclonal antibody against VE-cadherin (1 μg; Hycult Biotechnology, Plymouth Meeting, PA) was added to protein A-Sepharose beads (20 μl; Sigma-Aldrich) and incubated with gentle rocking overnight at 4°C. The protein A-Sepharose beads were pelleted by brief centrifugation and washed with immunoprecipitation buffer; 0.3 mg of cell lysate proteins was added to the protein A-Sepharose beads for 2 h at 4°C, after which the beads were washed and the pellet then resuspended in 20 μl of 2x Laemmli buffer. Twenty-microliter aliquots of immunoprecipitated protein were separated on 7% polyacrylamide SDS–PAGE gels and immunoblotted with antibodies to VE-cadherin or β-catenin (BD Transduction Laboratories).

**Transfection of siRNA**

Approximately 25,000 cells/well of six-well plates were grown to 50–70% confluence. Transfection with siRNAs was performed using transfection reagent and medium supplied by Santa Cruz Biotechnology, used in a final concentration of 50 nM. Approximately 25,000 cells/well of six-well plates were grown to 50–70% confluence. Transfection with siRNAs was performed using transfection reagent and medium supplied by Santa Cruz Biotechnology, used in a final concentration of 50 nM. After 7 h of incubation, an equal volume of transfection buffer was added to the transfected cells. After 18 h, the transfected cells were starved for 15 min in EBM-2 before treatment with apo(a).

**Prostaglandin E₂ assay**

HUVECs were grown to confluence in six-well tissue culture plates. Cells were starved for 15 min in EBM-2 and treated with 200 nM recombinant apo(a) (17K or 17K ΔAsp) or 2 ng/ml interleukin-1β. CM was collected at different time points, and the corresponding cells were pelleted by brief centrifugation and washed with immunoprecipitation buffer. The degree of labeling to the manufacturer’s specifications.

**Cell-binding assays**

Purified apo(a) was fluorescently labeled using Alexa Fluor 594 protein labeling kit (Invitrogen, Carlsbad, CA). The degree of labeling for all apo(a) preparations was 2.8–3 moles of dye per mole of protein. Human plasminogen labeled with fluorescein isothiocyanate was purchased from Molecular Innovations (Novi, MI). HUVECs, grown in 96-well plates with opaque well walls were washed three times with Hank’s balanced salt solution (HBSS)–0.4% bovine serum albumin (BSA) and fluorescently labeled r-apo(a) or plasminogen at a concentration of 400 nM and in the presence or absence of 200 mM e-ACA, was incubated with cells for 1 h at 37°C. After incubation, cells were washed once with HBSS–0.4% BSA, and the fluorescence was measured at an excitation wavelength of 590 nm and an emission wavelength of 617 nm using a plate-reading fluorescence spectrometer; a 610-nm cutoff filter was placed in the emission light path.

**REFERENCES**

Angeli DJ, Hyun SW, Grigoryev DN, Garg P, Gong P, Singh IS, Passaniti A, Hasday JD, Goldblum SE (2006). TNFα increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. Am J Physiol Lung Cell Mol Physiol 291, L1232–L1245.

Araki Y, Okamura S, Hussain SP, Nagashima H, Pe H, Shiseki M, Miura K, Harris CC (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63, 728–734.

Arbibe S, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch R, Knaus UG (2000). Toll-like receptor 2-mediated NFκB activation requires a Rac1-dependent pathway. Nat Immunol 1, 533–540.

Barbieri SS, Ruggiero L, Tremoli E, Weksler BB (2008). Suppressing PTEN activity by tobacco smoke plus interleukin-1β modulates dissociation of VE-cadherin/β-catenin complexes in endothelium. Arterioscler Thromb Vasc Biol 28, 732–738.

Barbieri SS, Weksler BB (2007). Tobacco smoke cooperates with interleukin-1β to alter β-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J 21, 1831–1843.

Behrens J, Jerchow BA, Wartele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W (1998). Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β. Science 280, 596–599.

Cho T, Jung Y, Koschinsky ML (2008). Apolipoprotein(a), through its strong lysine-binding site in KIV_10, mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem 283, 30503–30512.

Coffer PJ, Jin J, Woodgett JR (1998). Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335, 1–13.

Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789.

Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23, 254–266.

Dejana E, Orsenigo F, Lampugnani MG (2008). The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121, 2115–2122.

Donella-Deana A et al. (2003). Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem J 372, 841–849.

Downward J (1998). Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10, 262–267.

Dube JB, Bofts MB, Hegele RA, Koschinsky M (2012). Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol 23, 133–140.

Esser S, Lampugnani MG, Corada M, Dejana E, Risau W (1998). Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111, 1853–1865.

Esler M, Retzer M, Bauer M, Heemsker JW, Aepfelbacher M, Seiss W (1999). Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem 274, 30361–30364.

He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998). Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512.

Hemmings BA (1997). PtdIns(3,4,5)P3 gets its message across. Science 275, 17221–17226.

Hildesheim J, Salvador JM, Hollander MC, Fornace AJ Jr (2005). Casein kinase 2- and protein kinase A-regulated adenomatous polyposis coli and β-catenin cellular localization is dependent on p38 MAPK. J Biol Chem 280, 17221–17226.
Hughes SD, Lou XJ, Igkanis S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM (1997). Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 100, 1493–1500.

Janssens S, Buyaert R (2002). A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 27, 474–482.

Kim SJ, Im DS, Kim SH, Ryu JH, Hwang SG, Seong JK, Chun CH, Chun JS (2002). Beta-catenin regulates expression of cyclooxygenase-2 in articular chondrocytes. Biochem Biophys Res Commun 296, 221–226.

Koschinsky ML, Côté GP, Gabel B, van der Hoek YY (1993). Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 268, 19819–19825.

Koschinsky ML, Marcovina SM (2009). Lipoprotein(a). In: Clinical Lipidology: A Companion to Braunwald’s Heart Disease, ed. CM Ballantyne, Philadelphia: Saunders (Elsevier), 130–143.

Koschinsky ML, Tomlinson ZE, Zioncheck TF, Schwartz K, Eaton DL, Lawn RM (1999). Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry 30, 5044–5051.

Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E (2005). Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J 19, 115–117.

Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM (2008). Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 3, 107–110.

Maehama T, Dixon JE (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273, 13373–13378.

Maehama T, Taylor GS, Dixon JE (2001). PTEN and myotubularin: novel proteins structurally related in different species. EMBO J 8, 1711–1717.

McLean JW, Tomlinson JE, Kuang WH, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987). cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132–137.

O’Neil CH, Boffa MB, Hancock MA, Pickering JG, Koschinsky ML (2004). Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-β activation and on the presence of kringle IV type 9. J Biol Chem 279, 55187–55195.

Ozawa M, Banbuit H, Klemler R (1989). The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8, 1711–1717.

Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, Cho T, Cao K, Marcovina SM, Boffa MB, Côté GP, Koschinsky ML (2004). The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem 279, 6525–6533.

Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T (2007). Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 27, 1312–1318.

Sangar W, Gabel BR, Bozza MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJ, Nesheim ME, Koschinsky ML (1997). The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmgin-modified fibrinogen surface. Biochemistry 36, 10353–10363.

Sangar W, Koschinsky ML (2000). Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots. Biochim Cell Biol 78, 519–525.

Seimon TA et al. (2010). Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 12, 467–482.

Shasby DM, Ries DR, Shasby SS, Winter MC (2002). Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin. Am J Physiol Lung Cell Mol Physiol 282, L1330–L1338.

Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R, Ben-Ze’ev A (1999). The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96, 5522–5527.

Sotiriou SN et al. (2006). Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 20, 559–561.

Stemme V, Swedenborg J, Claesson H, Hansson GK (2000). Expression of cyclooxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg 20, 146–152.

Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H (1999). Modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96, 6199–204.

Tam SP, Zhang X, Koschinsky ML (1996). Interaction of a recombinant form of apolipoprotein(a) with human fibroblasts and with the human hematoma cell line HepG2. J Lipid Res 37, 518–533.

Tsimikas S, Hall JL (2012). Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol 60, 716–721.

Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR (2001). Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276, 48627–48630.

Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN (2006). Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc Natl Acad Sci USA 103, 3633–3638.

Vazquez F, Sellers WR (2000). The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470, M21–M35.

Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlic D, Menke A (2005). TGFβ-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 118, 4901–4912.

Wojciak-Stothard B, Entwistle A, Garg R, Ridley AJ (1998). Regulation of cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8, 1711–1717.